Generic Drugs Had Largest Quarterly AMP Fluctuations In OIG Study
Executive Summary
[June 14 Editor's Note: This is an updated version of a story originally published with the headline "Single-Source Drugs Show Greatest Overall AMP Fluctuation Between Quarters."]
You may also be interested in...
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.
Neurocrine Inks $575 Mil. Deal With Abbott To Develop and Sell Gynecologic, Elagolix
Elagolix could be the first oral drug approved for endometriosis that does not have severe side effects.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: